ProGRP: a new biomarker for small cell lung cancer

Molina, Rafael; Filella, Xavier; Augé, Josep M.

doi:10.1016/j.clinbiochem.2004.05.007

Cited by 123 publications

(135 citation statements)

References 31 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…NSE was considered to be the representative tumor marker for small cell lung cancer (SCLC). None of these markers are ideal (11)(12)(13)(14)(15)(16)(17)(18). In this study, the levels of these tumor markers simultaneously increased in 2 patients, which indicates poor performance of these tumor markers in the diagnosis of SMPLC.…”

Section: Discussionmentioning

confidence: 83%

Early clinical diagnosis of synchronous multiple primary lung cancer

Xue

Wang

et al. 2011

Oncology Letters

View full text Add to dashboard Cite

Abstract. The diagnosis of synchronous multiple primary lung cancer (SMPLC) remains a formidable challenge. The aim of the present study was to identify useful clues for the clinical diagnosis of SMPLC, in particular for the early stages. The medical records of 10 patients diagnosed with SMPLC with different histological types were analyzed retrospectively. Chest computed tomography (CT) findings showed two pulmonary lesions in all patients. The two lesions displayed malignant characteristics of primary lung cancer. The levels of a number of tumor markers, including carcinoembryonic antigen, neuron-specific enolase, cytokeratin fragment 21-1, squamous cell carcinoma and CA125 increased in 2 patients. Auxiliary examinations of other physical sites in these patients did not show signs of neoplasm metastasis. Two tumors were separately staged and appropriate treatment was carried out based on the revised stage, which provided more benefits for SMPLC patients. The diagnosis of SMPLC might be delayed or mistaken owing to its similarity to neoplasm metastasis. A high index of awareness is required for the early diagnosis of this disease. The malignant characteristics of primary lung cancer in various lesions may be valuable clues for the diagnosis of SMPLC. Alterations in the levels of tumor markers may be a poor diagnostic tool for the detection of SMPLC. Separate biopsies for different pulmonary masses should be performed for clinical staging as soon as possible and reasonable treatment based on the stage should also be selected.

show abstract

Section: Discussionmentioning

confidence: 83%

Early clinical diagnosis of synchronous multiple primary lung cancer

Xue

Wang

et al. 2011

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…On the other hand, 2 of the oncofetal antigens examined (proGRP and CA19-9) were persistently higher than the recommended adult cutoffs (23,32 ). Finally, at birth, the upper limit of the reference intervals for both CA15-3 and CA125 (24 and 22 U/mL) fell below the recommended adult cutoffs of 25 and 35 U/mL, respectively.…”

Section: Discussionmentioning

confidence: 98%

Pediatric Population Reference Value Distributions for Cancer Biomarkers and Covariate-Stratified Reference Intervals in the CALIPER Cohort

et al. 2014

View full text Add to dashboard Cite

BACKGROUND Cancer biomarkers are commonly used in pediatrics to monitor cancer progression, recurrence, and prognosis, but pediatric reference value distributions have not been well established for these markers. The Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) sought to develop a pediatric database of covariate-stratified reference value distributions for 11 key circulating tumor markers, including those used in assessment of patients with childhood or adult cancers. METHODS Healthy community children from birth to 18 years of age were recruited to participate in the CALIPER project with informed parental consent. We analyzed serum samples from 400–700 children (depending on the analyte in question) on the Abbott Architect ci4100 and established reference intervals for α-fetoprotein (AFP), antithyroglobulin (anti-Tg), human epididymis protein 4 (HE4), cancer antigen 125 (CA125), CA15-3, CA19-9, progastrin-releasing peptide (proGRP), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and total and free prostate specific antigen (PSA) according to CLSI C28-A3 statistical guidelines. RESULTS We observed significant fluctuations in biomarker concentrations by age and/or sex in 10 of 11 biomarkers investigated. Age partitioning was required for CA153, CA125, CA19-9, CEA, SCC, proGRP, total and free PSA, HE4, and AFP, whereas sex partitioning was also required for CA125, CA19-9, and total and free PSA. CONCLUSIONS This CALIPER study established a database of childhood reference intervals for 11 tumor biomarkers and revealed dramatic fluctuations in tumor marker concentrations between boys and girls and throughout childhood. In addition, important differences between the adult and pediatric population were observed, further highlighting the need for pediatric-specific reference intervals.

show abstract

“…Meanwhile, proGRP is a recently identified biomarker of SCLC (19), and some reports have indicated that the diagnostic usefulness of proGRP for SCLC is significantly higher than that of NSE (19,20). We studied proGRP in the sera of the present case and it was elevated preoperatively.…”

Section: Pulmonary Sequestration Is a Non-malignant Disease With A Famentioning

confidence: 93%